An observational study in Neurosurgical Patients, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Recruiting at 2 sites in Italy. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To compare the performance of the Eleveld models for propofol and remifentanil on neurosurgery patients admitted to intensive care with their intraoperative performance.
Despite the widespread adoption of Target Controlled Infusion (TCI) models in modern clinical anesthesia practice, much less attention has been paid in the literature to their potential applications in the Intensive Care Unit (ICU) setting. Few studies have been published so far to evaluate the performance of TCI pumps for sedatives and other drugs (e.g., antibiotics) in Intensive Care. Further data is needed regarding the use of TCI for the long-term infusion of these drugs in the ICU after surgery, and the quantitative relationship between generalized pharmacokinetic/pharmacodynamic models for propofol and remifentanil (the Eleveld models) has yet to be evaluated in this specific population. This study is an observational study with the aim of clarifying the predictive performance of the TCI models for the administration of propofol and remifentanil in a cohort of intensive care patients admitted after neurosurgery and compare it to the intraoperative performance, which can be taken as benchmark.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta is the lead sponsor of 84 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients undergoing elective neurosurgical procedures with an expected sedation after surgery of > 12 hours
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnancy
MdAPE difference for propofol
The difference in MdAPE will be measured when comparing the model performance for propofol in the ICU to the intraoperative phase.
Time frame: october 2024
MdAPE difference for remifentanil
The difference in MdAPE will be measured when comparing the model performance for remifentanil in the ICU to the intraoperative phase.
Time frame: october 2024
Propofol and remifentanil metabolites
Metabolites of propofol and remifentanil (4-hydroxy propofol and remifentanil acid) during infusion
Time frame: october 2024
BIS profile
Bispectral index monitor profile during infusion (min = 0, max = 100)
Time frame: october 2024
NOL profile
NOL (Nociceptive Level) value (min = 0, max = 100)
Time frame: Oct 2024
RASS
RASS measurements during infusion (min = -5, max = +4).
Time frame: october 2024
Plan to share: Yes — Propofol and remifentanil pharmacokinetic and pharmacodynamic data.
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta